MersV1, PascalFrancis, Corpus, bibRecord, 000009

Transmission of MERS-Coronavirus in Household Contacts

Identifieur interne : 000009 ( PascalFrancis/Corpus ); précédent : 000008; suivant : 000010

Transmission of MERS-Coronavirus in Household Contacts

Auteurs : Christian Drosten ; Benjamin Meyer ; Marcel A. Müller ; Victor M. Corman ; Malak Al-Masri ; Raheela Hossain ; Hosam Madani ; Andrea Sieberg ; Berend Jan Bosch ; Erik Lattwein ; Raafat F. Alhakeem ; Abdullah M. Assiri ; Waleed Hajomar ; Ali M. Albarrak ; Jaffar A. Al-Tawfiq ; Alimuddin I. Zumla ; Ziad A. Memish

Source :

The New England journal of medicine [ 0028-4793 ] ; 2014.

RBID : Pascal:14-0233350

Descripteurs français

Pascal (Inist)
- Transmission, Médecine, Coronavirus, Syndrome respiratoire du Moyen-Orient.

English descriptors

KwdEn :
- Coronavirus, Medicine, Middle East respiratory syndrome, Transmission.

Abstract

BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-4793`
A02	`01`			`@0 NEJMAG`
A03		`1`		`@0 N. Engl. j. med.`
A05				`@2 371`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Transmission of MERS-Coronavirus in Household Contacts`
A11	`01`	`1`		`@1 DROSTEN (Christian)`
A11	`02`	`1`		`@1 MEYER (Benjamin)`
A11	`03`	`1`		`@1 MÜLLER (Marcel A.)`
A11	`04`	`1`		`@1 CORMAN (Victor M.)`
A11	`05`	`1`		`@1 AL-MASRI (Malak)`
A11	`06`	`1`		`@1 HOSSAIN (Raheela)`
A11	`07`	`1`		`@1 MADANI (Hosam)`
A11	`08`	`1`		`@1 SIEBERG (Andrea)`
A11	`09`	`1`		`@1 JAN BOSCH (Berend)`
A11	`10`	`1`		`@1 LATTWEIN (Erik)`
A11	`11`	`1`		`@1 ALHAKEEM (Raafat F.)`
A11	`12`	`1`		`@1 ASSIRI (Abdullah M.)`
A11	`13`	`1`		`@1 HAJOMAR (Waleed)`
A11	`14`	`1`		`@1 ALBARRAK (Ali M.)`
A11	`15`	`1`		`@1 AL-TAWFIQ (Jaffar A.)`
A11	`16`	`1`		`@1 ZUMLA (Alimuddin I.)`
A11	`17`	`1`		`@1 MEMISH (Ziad A.)`
A14	`01`			`@1 Institute of Virology, University of Bonn Medical Center @2 Bonn @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 8 aut.`
A14	`02`			`@1 Euroimmun @2 Lubeck @3 DEU @Z 10 aut.`
A14	`03`			`@1 Global Center for Mass Gatherings Medicine, Ministry of Health @2 Riyadh @3 SAU @Z 3 aut. @Z 11 aut. @Z 12 aut. @Z 16 aut. @Z 17 aut.`
A14	`04`			`@1 Prince Sultan Military Medical City @2 Riyadh @3 SAU @Z 14 aut.`
A14	`05`			`@1 Alfaisal University @2 Riyadh @3 SAU @Z 17 aut.`
A14	`06`			`@1 Johns Hopkins Aramco Healthcare @2 Dhahran @3 SAU @Z 15 aut.`
A14	`07`			`@1 Regional Laboratory, Ministry of Health @2 Jeddah @3 SAU @Z 6 aut. @Z 7 aut.`
A14	`08`			`@1 Regional Laboratory, Ministry of Health @2 Riyadh @3 SAU @Z 13 aut.`
A14	`09`			`@1 Indiana University School of Medicine @2 Indianapolis @3 USA @Z 15 aut.`
A14	`10`			`@1 Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University @2 Utrecht @3 NLD @Z 9 aut.`
A14	`11`			`@1 Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals @2 London @3 GBR @Z 16 aut.`
A20				`@1 828-835`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6013 @5 354000507698850080`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 14-0233350`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The New England journal of medicine`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Transmission @5 07`
C03	`01`	`X`	`ENG`	`@0 Transmission @5 07`
C03	`01`	`X`	`SPA`	`@0 Transmisión @5 07`
C03	`02`	`X`	`FRE`	`@0 Médecine @5 08`
C03	`02`	`X`	`ENG`	`@0 Medicine @5 08`
C03	`02`	`X`	`SPA`	`@0 Medicina @5 08`
C03	`03`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 10`
C03	`03`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 10`
C03	`03`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 10`
C03	`04`	`X`	`FRE`	`@0 Syndrome respiratoire du Moyen-Orient @4 CD @5 96`
C03	`04`	`X`	`ENG`	`@0 Middle East respiratory syndrome @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`04`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Virose @5 38`
C07	`05`	`X`	`ENG`	`@0 Viral disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Virosis @5 38`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
N21				`@1 279`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0233350 INIST
ET :	Transmission of MERS-Coronavirus in Household Contacts
AU :	DROSTEN (Christian); MEYER (Benjamin); MÜLLER (Marcel A.); CORMAN (Victor M.); AL-MASRI (Malak); HOSSAIN (Raheela); MADANI (Hosam); SIEBERG (Andrea); JAN BOSCH (Berend); LATTWEIN (Erik); ALHAKEEM (Raafat F.); ASSIRI (Abdullah M.); HAJOMAR (Waleed); ALBARRAK (Ali M.); AL-TAWFIQ (Jaffar A.); ZUMLA (Alimuddin I.); MEMISH (Ziad A.)
AF :	Institute of Virology, University of Bonn Medical Center/Bonn/Allemagne (1 aut., 2 aut., 3 aut., 4 aut., 8 aut.); Euroimmun/Lubeck/Allemagne (10 aut.); Global Center for Mass Gatherings Medicine, Ministry of Health/Riyadh/Arabie Saoudite (3 aut., 11 aut., 12 aut., 16 aut., 17 aut.); Prince Sultan Military Medical City/Riyadh/Arabie Saoudite (14 aut.); Alfaisal University/Riyadh/Arabie Saoudite (17 aut.); Johns Hopkins Aramco Healthcare/Dhahran/Arabie Saoudite (15 aut.); Regional Laboratory, Ministry of Health/Jeddah/Arabie Saoudite (6 aut., 7 aut.); Regional Laboratory, Ministry of Health/Riyadh/Arabie Saoudite (13 aut.); Indiana University School of Medicine/Indianapolis/Etats-Unis (15 aut.); Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University/Utrecht/Pays-Bas (9 aut.); Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals/London/Royaume-Uni (16 aut.)
DT :	Publication en série; Niveau analytique
SO :	The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2014; Vol. 371; No. 9; Pp. 828-835; Bibl. 21 ref.
LA :	Anglais
EA :	BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.
CC :	002B01; 002B05C02C
FD :	Transmission; Médecine; Coronavirus; Syndrome respiratoire du Moyen-Orient
FG :	Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Virose; Infection
ED :	Transmission; Medicine; Coronavirus; Middle East respiratory syndrome
EG :	Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection
SD :	Transmisión; Medicina; Coronavirus
LO :	INIST-6013.354000507698850080
ID :	14-0233350

Links to Exploration step

Pascal:14-0233350

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Transmission of MERS-Coronavirus in Household Contacts</title>
<author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meyer, Benjamin" sort="Meyer, Benjamin" uniqKey="Meyer B" first="Benjamin" last="Meyer">Benjamin Meyer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A." last="Müller">Marcel A. Müller</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corman, Victor M" sort="Corman, Victor M" uniqKey="Corman V" first="Victor M." last="Corman">Victor M. Corman</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Al Masri, Malak" sort="Al Masri, Malak" uniqKey="Al Masri M" first="Malak" last="Al-Masri">Malak Al-Masri</name>
</author>
<author><name sortKey="Hossain, Raheela" sort="Hossain, Raheela" uniqKey="Hossain R" first="Raheela" last="Hossain">Raheela Hossain</name>
<affiliation><inist:fA14 i1="07"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Jeddah</s2>
<s3>SAU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Madani, Hosam" sort="Madani, Hosam" uniqKey="Madani H" first="Hosam" last="Madani">Hosam Madani</name>
<affiliation><inist:fA14 i1="07"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Jeddah</s2>
<s3>SAU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sieberg, Andrea" sort="Sieberg, Andrea" uniqKey="Sieberg A" first="Andrea" last="Sieberg">Andrea Sieberg</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jan Bosch, Berend" sort="Jan Bosch, Berend" uniqKey="Jan Bosch B" first="Berend" last="Jan Bosch">Berend Jan Bosch</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lattwein, Erik" sort="Lattwein, Erik" uniqKey="Lattwein E" first="Erik" last="Lattwein">Erik Lattwein</name>
<affiliation><inist:fA14 i1="02"><s1>Euroimmun</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhakeem, Raafat F" sort="Alhakeem, Raafat F" uniqKey="Alhakeem R" first="Raafat F." last="Alhakeem">Raafat F. Alhakeem</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Assiri, Abdullah M" sort="Assiri, Abdullah M" uniqKey="Assiri A" first="Abdullah M." last="Assiri">Abdullah M. Assiri</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hajomar, Waleed" sort="Hajomar, Waleed" uniqKey="Hajomar W" first="Waleed" last="Hajomar">Waleed Hajomar</name>
<affiliation><inist:fA14 i1="08"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Albarrak, Ali M" sort="Albarrak, Ali M" uniqKey="Albarrak A" first="Ali M." last="Albarrak">Ali M. Albarrak</name>
<affiliation><inist:fA14 i1="04"><s1>Prince Sultan Military Medical City</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name>
<affiliation><inist:fA14 i1="06"><s1>Johns Hopkins Aramco Healthcare</s1>
<s2>Dhahran</s2>
<s3>SAU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zumla, Alimuddin I" sort="Zumla, Alimuddin I" uniqKey="Zumla A" first="Alimuddin I." last="Zumla">Alimuddin I. Zumla</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Alfaisal University</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0233350</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0233350 INIST</idno>
<idno type="RBID">Pascal:14-0233350</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000009</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Transmission of MERS-Coronavirus in Household Contacts</title>
<author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meyer, Benjamin" sort="Meyer, Benjamin" uniqKey="Meyer B" first="Benjamin" last="Meyer">Benjamin Meyer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muller, Marcel A" sort="Muller, Marcel A" uniqKey="Muller M" first="Marcel A." last="Müller">Marcel A. Müller</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corman, Victor M" sort="Corman, Victor M" uniqKey="Corman V" first="Victor M." last="Corman">Victor M. Corman</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Al Masri, Malak" sort="Al Masri, Malak" uniqKey="Al Masri M" first="Malak" last="Al-Masri">Malak Al-Masri</name>
</author>
<author><name sortKey="Hossain, Raheela" sort="Hossain, Raheela" uniqKey="Hossain R" first="Raheela" last="Hossain">Raheela Hossain</name>
<affiliation><inist:fA14 i1="07"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Jeddah</s2>
<s3>SAU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Madani, Hosam" sort="Madani, Hosam" uniqKey="Madani H" first="Hosam" last="Madani">Hosam Madani</name>
<affiliation><inist:fA14 i1="07"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Jeddah</s2>
<s3>SAU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sieberg, Andrea" sort="Sieberg, Andrea" uniqKey="Sieberg A" first="Andrea" last="Sieberg">Andrea Sieberg</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jan Bosch, Berend" sort="Jan Bosch, Berend" uniqKey="Jan Bosch B" first="Berend" last="Jan Bosch">Berend Jan Bosch</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lattwein, Erik" sort="Lattwein, Erik" uniqKey="Lattwein E" first="Erik" last="Lattwein">Erik Lattwein</name>
<affiliation><inist:fA14 i1="02"><s1>Euroimmun</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhakeem, Raafat F" sort="Alhakeem, Raafat F" uniqKey="Alhakeem R" first="Raafat F." last="Alhakeem">Raafat F. Alhakeem</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Assiri, Abdullah M" sort="Assiri, Abdullah M" uniqKey="Assiri A" first="Abdullah M." last="Assiri">Abdullah M. Assiri</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hajomar, Waleed" sort="Hajomar, Waleed" uniqKey="Hajomar W" first="Waleed" last="Hajomar">Waleed Hajomar</name>
<affiliation><inist:fA14 i1="08"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Albarrak, Ali M" sort="Albarrak, Ali M" uniqKey="Albarrak A" first="Ali M." last="Albarrak">Ali M. Albarrak</name>
<affiliation><inist:fA14 i1="04"><s1>Prince Sultan Military Medical City</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name>
<affiliation><inist:fA14 i1="06"><s1>Johns Hopkins Aramco Healthcare</s1>
<s2>Dhahran</s2>
<s3>SAU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zumla, Alimuddin I" sort="Zumla, Alimuddin I" uniqKey="Zumla A" first="Alimuddin I." last="Zumla">Alimuddin I. Zumla</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name>
<affiliation><inist:fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Alfaisal University</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Medicine</term>
<term>Middle East respiratory syndrome</term>
<term>Transmission</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Transmission</term>
<term>Médecine</term>
<term>Coronavirus</term>
<term>Syndrome respiratoire du Moyen-Orient</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-4793</s0>
</fA01>
<fA02 i1="01"><s0>NEJMAG</s0>
</fA02>
<fA03 i2="1"><s0>N. Engl. j. med.</s0>
</fA03>
<fA05><s2>371</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Transmission of MERS-Coronavirus in Household Contacts</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DROSTEN (Christian)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MEYER (Benjamin)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MÜLLER (Marcel A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CORMAN (Victor M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>AL-MASRI (Malak)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HOSSAIN (Raheela)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MADANI (Hosam)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SIEBERG (Andrea)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JAN BOSCH (Berend)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LATTWEIN (Erik)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>ALHAKEEM (Raafat F.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ASSIRI (Abdullah M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>HAJOMAR (Waleed)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>ALBARRAK (Ali M.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>AL-TAWFIQ (Jaffar A.)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>ZUMLA (Alimuddin I.)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>MEMISH (Ziad A.)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Virology, University of Bonn Medical Center</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Euroimmun</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Global Center for Mass Gatherings Medicine, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Prince Sultan Military Medical City</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Alfaisal University</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Johns Hopkins Aramco Healthcare</s1>
<s2>Dhahran</s2>
<s3>SAU</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Jeddah</s2>
<s3>SAU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Regional Laboratory, Ministry of Health</s1>
<s2>Riyadh</s2>
<s3>SAU</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA20><s1>828-835</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6013</s2>
<s5>354000507698850080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0233350</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The New England journal of medicine</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Transmission</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Transmission</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Transmisión</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Médecine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Medicine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Medicina</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome respiratoire du Moyen-Orient</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Middle East respiratory syndrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>279</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0233350 INIST</NO>
<ET>Transmission of MERS-Coronavirus in Household Contacts</ET>
<AU>DROSTEN (Christian); MEYER (Benjamin); MÜLLER (Marcel A.); CORMAN (Victor M.); AL-MASRI (Malak); HOSSAIN (Raheela); MADANI (Hosam); SIEBERG (Andrea); JAN BOSCH (Berend); LATTWEIN (Erik); ALHAKEEM (Raafat F.); ASSIRI (Abdullah M.); HAJOMAR (Waleed); ALBARRAK (Ali M.); AL-TAWFIQ (Jaffar A.); ZUMLA (Alimuddin I.); MEMISH (Ziad A.)</AU>
<AF>Institute of Virology, University of Bonn Medical Center/Bonn/Allemagne (1 aut., 2 aut., 3 aut., 4 aut., 8 aut.); Euroimmun/Lubeck/Allemagne (10 aut.); Global Center for Mass Gatherings Medicine, Ministry of Health/Riyadh/Arabie Saoudite (3 aut., 11 aut., 12 aut., 16 aut., 17 aut.); Prince Sultan Military Medical City/Riyadh/Arabie Saoudite (14 aut.); Alfaisal University/Riyadh/Arabie Saoudite (17 aut.); Johns Hopkins Aramco Healthcare/Dhahran/Arabie Saoudite (15 aut.); Regional Laboratory, Ministry of Health/Jeddah/Arabie Saoudite (6 aut., 7 aut.); Regional Laboratory, Ministry of Health/Riyadh/Arabie Saoudite (13 aut.); Indiana University School of Medicine/Indianapolis/Etats-Unis (15 aut.); Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University/Utrecht/Pays-Bas (9 aut.); Division of Infection and Immunity, University College London (UCL), and National Institute for Health Research Biomedical Research Centre, UCL Hospitals/London/Royaume-Uni (16 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2014; Vol. 371; No. 9; Pp. 828-835; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>BACKGROUND Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission. METHODS We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing. RESULTS Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing. CONCLUSIONS The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.</EA>
<CC>002B01; 002B05C02C</CC>
<FD>Transmission; Médecine; Coronavirus; Syndrome respiratoire du Moyen-Orient</FD>
<FG>Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Virose; Infection</FG>
<ED>Transmission; Medicine; Coronavirus; Middle East respiratory syndrome</ED>
<EG>Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection</EG>
<SD>Transmisión; Medicina; Coronavirus</SD>
<LO>INIST-6013.354000507698850080</LO>
<ID>14-0233350</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000009 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000009 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0233350
   |texte=   Transmission of MERS-Coronavirus in Household Contacts
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Transmission of MERS-Coronavirus in Household Contacts

Transmission of MERS-Coronavirus in Household Contacts

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri